Online supplemental material:

Supplemental Table 1. Demographic and baseline clinical characteristics of the patients enrolled in the study stratified by completers and non-completers.

Supplemental Table 2. Effects of treatment with tesamorelin versus placebo on safety parameters.

Supplemental Table 3. Effects of treatment with tesamorelin versus placebo on fasting plasma glucose over time.

Supplemental Table 1. Demographic and baseline clinical characteristics of the patients enrolled in the study stratified by completers and non-completers.

	Completers (N= 36)	**Non-completers** (N= 24)	**P value**
Demographics			
Age (years)	42.4 ± 1.4	39.4 ± 1.6	0.17
Gender-M/F (% male)	22/14 (61%)	17/7 (71%)	0.44
Race (% Caucasian)	21 (58%)	14 (58%)	1.00
Current or Past Tobacco Use	18 (50%)	13 (54%)	0.75
Medication Use*			
HMG Co-A Reductase Inhibitor (%)	2 (6 %)	2 (8%)	0.67
Lipid lowering therapy† (%)	11 (31%)	9 (38%)	0.58
Anti-hypertensive (%)	11 (31%)	4 (17%)	0.22
Body Composition			
Weight (kg)	[111.5 (99.5, 128.8)]	[114 (104.6, 130.8)]	0.40
Body Mass Index (kg/m^2)	38.0 ± 0.8	38.2 ± 0.9	0.89
Waist Circumference (cm)	121 ± 2	125 ± 2	0.24
VAT (cm^2)	198 ± 11	206 ± 17	0.71
Growth Hormone Parameters			
Peak stimulated GH on GHRH-arginine stimulation test (µg/L)	4.71 ± 0.40	4.67 ± 0.58	0.95
IGF-1 (µg/L)	[120 (94, 148)]	[115 (76, 177)]	0.70

Results are presented as the mean ± SEM for normally distributed data and analyzed by Student's t-test. For data that is not normally distributed, results are presented as median with interquartile range (25%, 75%) and analyzed using the Wilcoxon rank sum test. Non-continuous variables are compared using χ^2 test. One patient in the non-completers group discontinued the study prior to obtaining baseline body composition data. *Medication use includes baseline data as well as initiation of new medications during the course of the study. †Lipid lowering medication use includes subjects using HMG Co-A reductase inhibitors, niacin and fish oil.

Abbreviations: HMG Co-A: 3-hydroxy-3-methyl-glutaryl-CoA reductase; VAT: abdominal visceral adipose tissue area (measured via abdominal computed tomography (CT) scan); GH: Growth hormone; GHRH: Growth hormone releasing hormone; IGF-1: Insulin-like growth factor-1.

Supplemental Table 2. Effect of treatment with tesamorelin versus placebo on safety parameters.

	Baseline			6-Month		12-Month		Change		Effect Size for Tesamorelin vs. placebo	
	Tesamorelin	Placebo	P value	Tesamorelin	Placebo	Tesamorelin	Placebo	Tesamorelin	Placebo	Effect Size (95% CI)	P value
Systolic BP (mm Hg)	121±2	120±2	0.89	120±2	124±2	120±2	123±2	-1±3	3±2	-5 (-11, 2)	0.15
Diastolic BP (mm Hg)	78±2	76±1	0.54	79±1	79±1	75±2	77±2	-3±2	1±1	-3 (-7, 1)	0.12
Fasting glucose (mg/dl)	95±3	92±2	0.79	95±5	88±2	98±5	92±3	2±3	1±2	1 (-5, 8)	0.73
2-hour glucose (mg/dl)	138±7	134±6	0.71	126±9	136±9	127±9	136±10	-11±7	-3±8	-10 (-27, 7)	0.25
Insulin (μU/ml)	9.3±1.1	8.6±0.9	0.78	12.7±3.3	9.3±1.0	13.3±3.3	10.4±1.2	4.0±3.3	1.8±1.0	-0.3 (-7.5, 7.0)	0.94
HOMA-IR	2.25±0.29	1.98±0.21	0.69	3.42±1.08	2.03±0.22	3.59±1.08	2.47±0.33	1.46±1.08	0.50±0.26	-0.11 (-2.41, 2.19)	0.93
HbA1c (%)	5.8±0.1	5.6±0.1	0.26	6.1±0.1	5.8±0.1	6.0±0.1	5.8±0.1	0.2±0.1	0.2±0.1	-0.002 (-0.2, 0.2)	0.98
AST (U/L)	25±3	25±2	0.52	25±3	29±3	25±3	26±3	-1±2	1±2	-1 (-8, 5)	0.71
ALT (U/L)	29±3	30±4	0.61	29±5	34±4	27±4	29±3	-2±2	-1±2	-1 (-8, 5)	0.69

Results are presented as mean ± SEM. P value from baseline data are obtained by Student's t-test for normally distributed variables and Wilcoxon rank sum for non-normally distributed samples. Effects size and P values were obtained by longitudinal linear mixed effects modeling for each parameter over 12 months with last value carried forward. One patient in the tesamorelin group discontinued the study prior to obtaining baseline body composition and biochemical data.

Abbreviations: HbA1c: Hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase.

Supplemental Table 3. Effects of treatment with tesamorelin versus placebo on fasting plasma glucose over time.

	Baseline	2-Weeks	1-Month	3-Month	6-Month	9-Month	12-Month
Tesamorelin	95±3	97±2	95±2	96±3	95±5	96±3	93±3
Placebo	92±2	93±3	92±2	93±2	87±2	94±3	93±4
P value	0.69	0.60	0.65	0.60	0.18	0.74	0.90

Results are presented as mean ± SEM. P value for each visit was obtained by longitudinal linear mixed effects modeling.